Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742684 | 1.00 | KMT2A (0.62) | KMT2APOLBLMNAMMP9TDP1 | |
| SCHEMBL7748692 | 0.94 | KMT2A (0.69) | KMT2APOLBLMNAMMP9TDP1 | |
| SCHEMBL7748698 | 0.94 | KMT2A (0.69) | KMT2APOLBLMNAMMP9TDP1 | |
| SCHEMBL19449621 | 0.88 | KMT2A (0.57) | KMT2APOLBLMNAMMP9TDP1 | |
| Hydrochloric Acid SCHEMBL17560782 | 0.87 | KMT2A (0.56) | KMT2APOLBLMNAMMP9TDP1 | |
| SCHEMBL24278353 | 0.86 | GAA (0.43) | KMT2APOLBGAAMEN1KDM4E | |
| SCHEMBL7743096 | 0.85 | HPGD (0.68) | KMT2APOLBLMNAMMP9MAPT | |
| SCHEMBL7743100 | 0.85 | HPGD (0.68) | KMT2APOLBLMNAMMP9MAPT | |
| SCHEMBL12766462 | 0.84 | MMP9 (0.75) | KMT2APOLBLMNAMMP9MAPT | |
| SCHEMBL7747080 | 0.84 | SMN1; SMN2 (0.64) | KMT2APOLBLMNAMMP9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | claimed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | KMT2A 2497/4885POLB 1424/4885LMNA 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.